Fig. 3

Survival probability by MFC-MRD status at TP1 and TP2. According to the MFC-MRD levels at TP1 and TP2, patients were stratified into two groups based on MFC-MRD (MFC-MRD < 0.1%; MFC-MRD ≥ 0.1%). EFS (a), OS (b), and CIR (c) according to MFC-MRD at TP1. EFS (d), OS (e), and CIR (f) according to MFC-MRD at TP2. EFS, event-free survival; OS, overall survival; CIR, cumulative incidence of relapse; MFC, multiparametric flow cytometry; MRD, minimal residual disease, TP1, on days 28–35 after the first induction course; TP2, at the end of the second induction course (before start of consolidation)